Sysmex

Sysmex Short-term Debt

The Short-Term Debt of Sysmex (6869.T) as of Oct 21, 2026 is 9.56 B JPY. In the previous year, Short-Term Debt was 9.25 B JPY — a change of 3.30% (higher).

Short-term Debt

9.56 BJPY

YoY

3.30%

Last updated:

Short-Term Debt of Sysmex is 2026 9.56 B JPY. Short-Term Debt of Sysmex was 2025 9.25 B JPY. It decreases by 3.30% higher compared to the previous year.

The Sysmex Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2019
192.00 M JPY
Jan 1, 2020
5.70 B JPY
Jan 1, 2021
5.78 B JPY
Jan 1, 2022
6.44 B JPY
Jan 1, 2023
7.15 B JPY
Jan 1, 2024
8.66 B JPY
Jan 1, 2025
9.25 B JPY
Jan 1, 2026
9.56 B JPY
The Sysmex Short-term Debt history
YEARShort-term DebtYoY
9.56 BJPY+3.30%
9.25 BJPY+6.83%
8.66 BJPY+21.12%
7.15 BJPY+11.03%
6.44 BJPY+11.34%
5.78 BJPY+1.44%
5.70 BJPY+2,869.27%
192.00 MJPY+6.67%
180.00 MJPY+5.88%
170.00 MJPY+14.09%
149.00 MJPY+198.00%
50.00 MJPY-95.48%
1.11 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sysmex Stock analysis

What does Sysmex do? Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide. History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972. Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology. Divisions: Sysmex Corp is divided into three main business divisions: 1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. 2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory. 3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue. Products: Sysmex offers a variety of products, including: - Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets. - Hemostasis systems for analyzing blood coagulation. - Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. - Urinalysis systems for analyzing urine samples for chemical and microscopic parameters. - Immunology analysis devices for determining specific proteins and antibodies in the blood. - Clinical chemistry analysis devices for analyzing chemical parameters in blood samples. - Software and IT solutions for optimizing laboratory processes and management. - Cell analysis and imaging systems for investigating cell morphology and functions. - Devices for harvesting mesenchymal stem cells from adipose tissue. In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences. Sysmex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sysmex stock

Short-Term Debt of Sysmex is 9.56 B JPY in 2026.

Short-Term Debt of Sysmex changed from 9.25 B JPY to 9.56 B JPY, representing a 3.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Sysmex since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Sysmex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sysmex

All Key Metrics — Sysmex